A breast cancer vaccine shows promising results UW study finds Axios Seattle

A breast cancer vaccine shows promising results UW study finds Axios Seattle

A breast cancer vaccine shows promising results, UW study finds - Axios SeattleLog InLog InAxios Seattle is an Axios company.

A vaccine for breast cancer may be near

Illustration: Lindsey Bailey/Axios An experimental vaccine may be able to prevent or treat a particularly aggressive form of breast cancer, according to new findings from UW Medicine researchers. Driving the news: In a decade-long Phase I human trial, the vaccine created a strong immune response to proteins that cause tumors to grow aggressively, researchers said in this month. Why it matters: About 264,000 cases of breast cancer are diagnosed annually in women and about 2,400 in men in the U.S., . What they're saying: "I have very high hopes that it is close to the final step of this vaccine potentially becoming a treatment for patients with breast cancer," said the study's lead author Mary "Nora" Disis, a professor at the University of Washington School of Medicine and director of the . Disis said the vaccine was found to be "very safe" in the Phase 1 trial, with the most common side effects being similar to those of the COVID vaccine: Soreness at the injection site and flu-like symptoms for a few days. How it works: The vaccine targets a protein called human epidermal growth factor receptor 2 (HER2). HER2 is overproduced by as much as a hundredfold in as many as 30% of breast cancers, according to UW Medicine. "HER2-positive" cancers tend to be more aggressive and more likely to recur after treatment, Disis said. But the overproduction of HER2 may also trigger a beneficial cell-killing immune reaction in some. Recurrence is lower and survival rates are higher in people who have that immune response.To harness that reaction, Disis and her colleagues created a DNA vaccine which is absorbed by cells at the site of the injection. Those cells then start to produce the protein encoded in the vaccine’s DNA instructions which prompts a strong cytotoxic immune response, the study found. What's next: Patients with HER2 breast cancer are being recruited for the . For more information contact the patient coordinator: or call 206-543-3829. . Get more local stories in your inbox with .Subscribe Support local journalism by becoming a member.

More Seattle stories

No stories could be found Get a free daily digest of the most important news in your backyard with Axios Seattle.Subscribe Support local journalism by becoming a member.
Share:
0 comments

Comments (0)

Leave a Comment

Minimum 10 characters required

* All fields are required. Comments are moderated before appearing.

No comments yet. Be the first to comment!